The Compounded GLP-1 Compliance Calendar: Every FDA Deadline Through 2026

Every deadline that actually binds a compounded GLP-1 program has already passed. FDA enforcement discretion ended for tirzepatide on March 19, 2025 and for semaglutide on May 22, 2025. The only live date left in 2026 is July 30, when the comment period closes on FDA's proposal to keep semaglutide, tirzepatide and liraglutide off the 503B bulks list. Nothing has been finalized.

This post is a calendar, not an argument. If you want the narrative version of how the category collapsed, read what the resolved semaglutide shortage actually changed. What follows is the dated sequence: which dates are closed and binding, which are still moving, and what an operator should have done before each one. Where a date is genuinely unresolved, it is marked unresolved rather than guessed.

What FDA deadlines have already passed for compounded GLP-1s?

The shortage resolutions and the wind-down windows that followed them are all in the past. Tirzepatide came off the shortage list in October 2024 and the determination was reaffirmed in December 2024. Semaglutide was declared resolved on February 21, 2025. Every enforcement-discretion window tied to those determinations closed during 2025.

Date	What changed	Who it binds	Operator action, in hindsight
October 2024, reaffirmed December 2024	FDA declared the tirzepatide shortage resolved	503A pharmacies and 503B facilities	Stop treating shortage status as a durable product basis
February 21, 2025	FDA declared the semaglutide shortage resolved	503A pharmacies and 503B facilities	Same trigger, second molecule, roughly four months later
March 5, 2025	The Northern District of Texas denied the Outsourcing Facilities Association's preliminary injunction over the tirzepatide delisting	Anyone relying on litigation to reopen the window	Stop planning around a court stay that did not arrive
March 13 and March 19, 2025	Enforcement discretion for compounded tirzepatide ended for 503A pharmacies, then for 503B outsourcing facilities	Both compounder classes	Remove tirzepatide SKUs, rewrite marketing copy
April 22 and May 22, 2025	Enforcement discretion for compounded semaglutide ended for 503A pharmacies, then for 503B outsourcing facilities	Both compounder classes	Same, for semaglutide; last routine date on the calendar

The March 2025 sequence is worth reading closely because it shows how FDA times these things. The agency had said it would hold off on tirzepatide until February 18, 2025 or until the district court ruled on the preliminary injunction, whichever came later. The court denied the motion on March 5, and FDA announced that 503A discretion had ended on March 13, as reported by the National Community Pharmacists Association. Litigation bought a few weeks of runway, not a reversal.

One more closed date belongs on the list. On September 5, 2025, FDA established an import alert and a "green list" of foreign GLP-1 active ingredient manufacturers it had inspected or evaluated, allowing APIs from any other source to be detained at the border without physical examination. Commissioner Marty Makary framed it as "taking aggressive action to protect consumers from poor-quality or dangerous GLP-1 drugs." For an operator, that date matters because it moved the constraint upstream, into your pharmacy partner's supply chain, where you have the least visibility.

What is the only live GLP-1 compounding deadline in 2026?

July 30, 2026, and it is a comment deadline rather than a compliance deadline. On April 30, 2026 FDA announced it was proposing not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list, finding no clinical need. The notice published May 1, 2026 at 91 Fed. Reg. 23431, docket FDA-2018-N-3240.

Date	Status	Who it binds	What to do
April 1, 2026	FDA statement restating the conditions for 503A and 503B exemptions, including its policy of not acting where a compounder fills four or fewer prescriptions of an essentially-a-copy product in a calendar month	503A and 503B compounders	Treat as discretionary policy, not a safe harbor you can scale into
May 1, 2026	Proposal published, 91 Fed. Reg. 23431, docket FDA-2018-N-3240; original comment close June 30, 2026	503B outsourcing facilities	Read it; it is a proposal, not a rule
June 26, 2026	FDA extended the comment period by 30 days, to July 30, 2026, in response to a request for more time	Anyone commenting	File by July 30 if you intend to be on the record
After July 30, 2026	FDA reviews comments and issues a final determination	503B outsourcing facilities	Unresolved. No statutory date has been published
Unresolved	Demonstrable difficulties for compounding rulemaking, proposed March 20, 2024, still not final	Both classes, if GLP-1s are ever added	Monitor. Do not assume it is coming or that it is not

The practical read is narrow. If finalized as proposed, the determination would foreclose 503B compounding of these three molecules from bulk drug substances even if a future shortage were declared, which is a stronger outcome than the 2025 wind-downs produced. But it is not law today, and treating a proposal as a final rule is how operators end up making expensive decisions twice.

Does the 503B bulks proposal change anything for a 503A pharmacy?

Not directly. The proposal concerns the 503B bulks list and does not amend the 503A framework. 503A pharmacies may still compound using active ingredients that are components of FDA-approved drug products, subject to the other statutory conditions. What constrains them is the same thing that has constrained them since the shortage resolutions: the "essentially a copy" restriction.

That distinction gets blurred constantly in operator conversations, and the blur is expensive because the two classes were closed off by different mechanisms on different dates. If your fulfillment runs through an outsourcing facility, the 2026 proposal is the thing to watch. If it runs through a state-licensed pharmacy, the 2025 dates already decided your position and nothing in the 2026 docket will change it. The mechanics of each are laid out in how 503A and 503B compounding actually differ.

What does "personalization" actually buy an operator?

Very little at scale. FDA's April 1, 2026 statement restated that a compounded product is essentially a copy when it has the same active ingredient as a commercially available product in the same, similar or easily substitutable strength by the same route, unless the prescriber determines and documents a change that produces a significant difference for an identified individual patient, as summarized by Foley & Lardner.

Read that sentence as a documentation requirement placed on a named clinician, per patient, not as a formulation trick. Two things follow:

• A uniform "personalized" dose applied to every patient is a pattern, and patterns are what regulators examine. Identical customization across a book of patients is evidence against individualization, not for it.
• The policy of not pursuing a compounder who fills four or fewer such prescriptions in a calendar month is enforcement discretion, published by an agency that can revise it. It describes a rounding error, not a business model.

There is also a hard number on what the industry did with those arguments. A study published in JAMA Health Forum on July 17, 2026 (DiStefano MJ, et al.) surveyed 75 businesses in two states between August and October 2025, after the May 22, 2025 date. It found 92% still selling compounded semaglutide and 86.7% selling compounded tirzepatide, with 58.7% offering compounded medications containing additives. Of the 23 supplying pharmacies identified, 13% were registered with FDA as 503B outsourcing facilities. That is the gap between what the calendar said and what the market did, and it is the reason FDA sent 30 warning letters to telehealth companies on March 3, 2026 over marketing that implied equivalence to approved products. The marketing exposure is a separate and often earlier failure mode, covered in what the telehealth warning letters actually cited.

Is semaglutide going on the "demonstrable difficulties" list?

Unresolved, and the question is frequently confused with the 503B bulks proposal. They are different instruments. The demonstrable difficulties for compounding rulemaking was proposed on March 20, 2024, with comments due June 18, 2024, and its initial proposed categories are oral solid modified-release products, liposome products, and products made using hot-melt extrusion. GLP-1s are not among them.

Separately, Novo Nordisk nominated semaglutide to that list in October 2024. A nomination is a request, not an outcome. As of late July 2026 there is no verified final FDA action adding semaglutide, tirzepatide or liraglutide to a demonstrable difficulties list, and anyone telling you there is should be asked for the Federal Register citation. The honest operator position is that a second, broader restriction mechanism exists, it would reach 503A as well as 503B if used, and its timing is unknown.

What did the July 2026 peptide votes change for diversification?

Nothing yet, and that is the point. On July 23 and 24, 2026 FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides nominated for the 503A bulks list. It voted in favor of BPC-157, KPV and TB-500 (8-6 with one abstention each) and MOTS-c (7-5 with two abstentions) on the first day, and in favor of Semax (8-5 with one abstention) and Epitalon (7-5 with one abstention, per RAPS) on the second, rejecting emideltide, also called DSIP, by 6-7 with one abstention.

Those are recommendations. The committee does not make law, its votes ran against FDA's own scientific review team, which had recommended against all seven, and FDA has said any final decision comes through notice-and-comment rulemaking rather than at the meeting, as reported by the FDA Law Blog. Until a substance is actually placed on the 503A bulks list, a favorable vote changes nothing about what a pharmacy may lawfully compound.

For operators diversifying out of GLP-1, this is a useful stress test of the plan. If a category you are counting on is itself waiting on a bulks-list determination, you have swapped one regulatory dependency for another. Category expansion into peptides and hormones works when the categories carry independent legal footing, not when they share a single pending docket.

What should be on an operator's compliance calendar now?

Two live items and a set of standing controls. The live items are the July 30, 2026 comment close and the undated FDA final determination that follows it. Everything else is structural.

Before the next formulary change

1. Get your pharmacy partner's written legal basis for every compounded SKU you sell, citing the specific statutory condition it relies on. Verbal confidence is not a basis.
2. Audit marketing copy for equivalence and sameness claims, and for product names that imply your brand compounded the drug. This is what the March 3, 2026 letters cited.
3. Confirm which class each partner falls into, 503A or 503B, because the two are governed by different dockets and different dates.
4. Map revenue concentration by molecule. If any single molecule carries more than half the book, the regulatory floor under it is also the floor under the business.

Standing controls that survive any docket

A licensed provider approves every order, every time. That does not change with a shortage list, a bulks list or an advisory vote, and it is the control most likely to be examined if anything else goes wrong. Beyond that, the durable position is category breadth plus a routing layer that turns a category change into a configuration change rather than a rebuild. Non-controlled 503A remains the safe default framing for most operators. If adding or retiring a category means renegotiating a platform contract or migrating patient records, the regulatory calendar is not your real problem. How multi-pharmacy routing works covers the mechanics.

neolife is deliberately not a GLP-1 company. It is the fulfillment rail that sits on top of the compounding pharmacy a clinic already uses, so that when a docket closes or a bulks list changes, the response is a routing rule rather than a rebuild. Operators keep their own storefront, stay the system of record for their patients, and add pharmacies without a rip-and-replace. If you are rebuilding a formulary around dates you do not control, talk to us.

This article is for informational purposes only and is not legal, medical, or regulatory advice; consult qualified counsel and licensed clinicians for your specific situation.